Evidence map›Paper›PMID 31782137›Full record

ArticleInternational journal of cancer2020

Divergent breast cancer incidence trends by hormone receptor status in the state of Sarawak, Malaysia.

Hyuna Sung, Beena C R Devi, Tieng S Tang, Philip S Rosenberg, William F Anderson, Xiaohong R Yang

Open access · greenAbstract read
In one paragraph

Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Epidemiology of Uterine Cancer in Sarawak, Borneo, A 20-Year Review.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Hyuna SungSurveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.ORCID 0000-0002-8021-5997
Beena C R DeviDepartment of Radiotherapy, Oncology and Palliative Care, Sarawak General Hospital, Kuching, Sarawak, Malaysia.
Tieng S TangDepartment of Radiotherapy, Oncology and Palliative Care, Sarawak General Hospital, Kuching, Sarawak, Malaysia.
Philip S RosenbergDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
William F AndersonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
Xiaohong R YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.ORCID 0000-0003-4451-8664
National Institutes of Health · USSarawak General Hospital · MYAmerican Cancer Society · US

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Genetic EpidemiologyZIACP005803 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GOLDSTEIN, ALISA · 2009 to 2025
$24.8M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA CP005803
6 · The paper itself

Abstract

Recent studies from high-risk countries such as the US, Denmark and Ireland have shown rising incidence rates of hormone receptor (HR)-positive and falling rates of HR-negative breast cancers (BC). However, it remains unclear whether a similar pattern occurs in low-risk countries. Detailed clinical and risk factor data were collected from 2,977 female invasive BC patients (≥20 years) in Sarawak General Hospital, Malaysia, representing 93% of the population. The population-at-risk was obtained from the Department of Statistics Malaysia. Secular trends in age-standardized incidence rates were assessed using estimated average annual percent changes. Associations between established BC risk factors and tumor subtypes defined by HR or joint human epidermal growth factor receptor 2 (HR/HER2) status were examined by case-case comparisons using logistic regression. From 2006 to 2015, incidence rates increased for HR-positive cancers by 4.46%/year (95% CI = 2.19-6.78) and decreased for HR-negative cancers by 2.29%/year (95% CI = -4.31 to -0.24). When further stratified by HER2, the most contrasting difference in linear trends was observed between HR+/HER2- and HR-/HER2- subtypes. After controlling for potential confounders, cases with excess body weight (OR

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansIncidenceMalaysiaMiddle AgedYoung AdultERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesbreast cancerhormone receptor negative cancerhormone receptor positive cancerincidence trendMalaysia

Identifiers

PMID31782137
PMCPMC8268183
OpenAlexW2990888466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.